SeaStar Medical Holding Corporation, a commercial-stage healthcare company, develops a proprietary platform therapy to reduce the consequences of hyperinflammation on vital organs in the United States. The company offers the selective cytopheretic device (SCD), which is a disease-modifying device that neutralizes over-active immune cells and stops the cytokine storm that yields destructive hyperinflammation; and QUELIMMUNE, an SCD therapy for pediatric patients with acute kidney injury (AKI) due to sepsis. It also develops NEUTRALIZE-AKI, an SCD therapy that is in clinical trials for adult patients with AKI; and other products in various therapeutic areas, including cardiorenal syndrome, hepatorenal syndrome, and myocardial stunning in end-stage renal disease. SeaStar Medical Holding Corporation was founded in 2007 and is headquartered in Denver, Colorado.…
ICU: QUELIMMUNE® Commercial Adoption Continues; Adult AKI Study Progresses Toward 2027 Completion
SeaStar Medical Holding (NASDAQ: ICU) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 18 employees.
The shares were at 0.9350 USD on 20 November 2026, down 80.9% over 52 weeks. Its 52-week range is 0.7788 USD to 5.380 USD: the price is 82.6% below the high and 20.1% above the low.
Its market capitalisation is 4.97M USD.
SeaStar Medical Holding reports return on equity of -116.6% and revenue up 82.0% year over year.
It holds more cash than debt, a net cash position of 6.83M USD. Its Piotroski F-score is 4 out of 9, an average reading of its financial health.